Table 3.

Nonclinical safety evaluation in cynomolgus monkeys.

	HB0017	HB0034	HB0043*
Animal species	Cynomolgus monkey	Cynomolgus monkey	Cynomolgus monkey
Route of administration	Subcutaneous	Intravenous	Intravenous
Dosage (mg/kg)	15, 50, 150	50, 100, 250	20, 100, 200
Dosing cycle	Once a week, a total of 5 doses	Once a week, a total of 5 doses	Once a week, a total of 5 doses
NOAEL	150 mg/kg	250 mg/kg	200 mg/kg
Main toxicological findings	IgG level elevated and local inflammation and/or hemorrhage observed.	Total protein, globulin concentration, and IgG occasionally increased.	After the 3rd and 5th dosage, 200 mg/kg group GLB increased, A/G decreased; 200 mg/kg group males TP increased, IgG increased in 100, 200 mg/kg groups.